Christoph Niederhauser1,2,3, Caroline Tinguely1, Jens Dreier4, Tanja Vollmer4, Hans Peter Marti5,6, Beatrice Nickel5,6, Julia Maria Klemens7, Jens Miguel Warnecke7, Peter Gowland1. 1. Interregional Blood Transfusion SRC, Bern, Switzerland. 2. Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Bern, Switzerland. 3. Faculté de Biologie et de Médecine, Université de Lausanne, Lausanne, Switzerland. 4. Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Germany. 5. Swiss Tropical and Public Health Institute, Basel, Switzerland. 6. University of Basel, Basel, Switzerland. 7. Institute for Experimental Immunology, EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany.
Abstract
BACKGROUND: Malaria is a mosquito-borne infectious disease caused by protozoan parasites of the genus Plasmodium. As migration of populations from endemic areas to Europe and overseas recreational travel to endemic regions increase, there is also a growing risk of transfusion-transmitted tropical diseases by blood components. MATERIAL AND METHODS: In the present study two routine Plasmodium spp. ELISA (CAPTIA™ Malaria EIA, Trinity Biotech, and Malaria EIA, BioRad) were compared with a new commercial ELISA (ELISA IgG, EUROIMMUN). From December 1, 2015 until November 30, 2016, 1,096 plasma samples from blood donors with a potential risk of malaria infection were collected at two blood transfusion centres in Germany and Switzerland. RESULTS: The samples were tested comparatively with the ELISA from EUROIMMUN and the routine test used at the respective centre. Thirty-four of 595 (5.7%) tested blood samples from centre 1 and 49 of 501 (9.8%) tested blood samples from centre 2 showed reactivity on either or both ELISAs. All 83 reactive samples were sent for confirmation to the Diagnostic Centre of the Swiss Tropical and Public Health Institute (Swiss TPH) in Basel, Switzerland. Sixteen samples, which previously were reactive in the routine Plasmodium spp. EIA assays, were proven positive after confirmation testing (i.e., 4 positive and 12 inconclusive results), indicating an anti-Plasmodium antibody prevalence in blood donations of 1.5%. From these 16 reactive samples, 13 were also detected by the index test, resulting in an assay sensitivity of 81.2%. A specificity of 98.6% was calculated (1,065/1,080 confirmed negative samples). The overall agreement with the reference centre was 95.8% in centre 1 and 94% in centre 2. CONCLUSION: The comparison of the new EUROIMMUN ELISA and the established CAPTIA™ Malaria EIA (Trinity Biotech) and Malaria EIA (BioRad) used for routine blood donor screening in two laboratory blood donation centres revealed that all tested ELISAs show comparable sensitivities and are equally suitable for anti-Plasmodium antibody screening in blood banks.
BACKGROUND: Malaria is a mosquito-borne infectious disease caused by protozoan parasites of the genus Plasmodium. As migration of populations from endemic areas to Europe and overseas recreational travel to endemic regions increase, there is also a growing risk of transfusion-transmitted tropical diseases by blood components. MATERIAL AND METHODS: In the present study two routine Plasmodium spp. ELISA (CAPTIA™ Malaria EIA, Trinity Biotech, and Malaria EIA, BioRad) were compared with a new commercial ELISA (ELISA IgG, EUROIMMUN). From December 1, 2015 until November 30, 2016, 1,096 plasma samples from blood donors with a potential risk of malaria infection were collected at two blood transfusion centres in Germany and Switzerland. RESULTS: The samples were tested comparatively with the ELISA from EUROIMMUN and the routine test used at the respective centre. Thirty-four of 595 (5.7%) tested blood samples from centre 1 and 49 of 501 (9.8%) tested blood samples from centre 2 showed reactivity on either or both ELISAs. All 83 reactive samples were sent for confirmation to the Diagnostic Centre of the Swiss Tropical and Public Health Institute (Swiss TPH) in Basel, Switzerland. Sixteen samples, which previously were reactive in the routine Plasmodium spp. EIA assays, were proven positive after confirmation testing (i.e., 4 positive and 12 inconclusive results), indicating an anti-Plasmodium antibody prevalence in blood donations of 1.5%. From these 16 reactive samples, 13 were also detected by the index test, resulting in an assay sensitivity of 81.2%. A specificity of 98.6% was calculated (1,065/1,080 confirmed negative samples). The overall agreement with the reference centre was 95.8% in centre 1 and 94% in centre 2. CONCLUSION: The comparison of the new EUROIMMUN ELISA and the established CAPTIA™ Malaria EIA (Trinity Biotech) and Malaria EIA (BioRad) used for routine blood donor screening in two laboratory blood donation centres revealed that all tested ELISAs show comparable sensitivities and are equally suitable for anti-Plasmodium antibody screening in blood banks.
Authors: H W Reesink; S Panzer; S Wendel; J E Levi; H Ullum; S Ekblom-Kullberg; E Seifried; M Schmidt; E Shinar; D Prati; A Berzuini; S Ghosh; Ø Flesland; S Jeansson; E Zhiburt; M Piron; S Sauleda; B Ekermo; R Eglin; A Kitchen; R Y Dodd; D A Leiby; L M Katz; S Kleinman Journal: Vox Sang Date: 2010-01-28 Impact factor: 2.144
Authors: Patricia Scuracchio; Sergio Domingos Vieira; Denise Albuquerque Dourado; Luciana Moro Bueno; Rafael Colella; Eduardo Milton Ramos-Sanchez; Giselle F M Castro Lima; Juliana Inoue; Maria Carmen Arroyo Sanchez; Silvia Maria Di Santi Journal: Rev Inst Med Trop Sao Paulo Date: 2011 Jan-Feb Impact factor: 1.846
Authors: Rosemary C She; Mindy L Rawlins; Ramsey Mohl; Sherrie L Perkins; Harry R Hill; Christine M Litwin Journal: J Travel Med Date: 2007 Mar-Apr Impact factor: 8.490